Drug Formulary information is intended for use by healthcare professionals. It is not intended to be medical advice. Some of the information, including information about funding for cancer drugs, does not apply to all patients. Cancer treatment plans are unique to each patient. If you are a patient, please speak with your healthcare team to understand how this information applies to you.
Severe weather warning in your area. Please stay indoors and stay safe. Read more
regimen
DEXAPOMA+ISAT
- Cancer Type
- Hematologic, Multiple Myeloma
- Intent
-
Palliative
- Regimen Category
-
Evidence-Informed
- Funding Program
-
New Drug Funding Program Isatuximab - In Combination with Pomalidomide and Dexamethasone for Relapsed or Refractory Multiple Myeloma Exceptional Access Program pomalidomide - In combination with isatuximab and dexamethasone for relapsed and/or refractory multiple myeloma, according to specific criteria ODB - General Benefit dexamethasone
- Drugs Used
- dexamethasone , isatuximab , pomalidomide
Regimen Monograph
Feb 2024
Patient Info Sheet
Please see Drugs Used for related Patient Information Sheets. Patient Information Sheets are not yet available for this regimen.
Last Updated: July 21, 2026
